2nd Next Generation Kinase Inhibitors Summit
Oncology
Join us again at the only FREE TO ATTEND (for drug developers & academics) industry-dedicated summit focused on advancing the best-in-class kinase inhibitor products with enhanced specificity, resistance, and safety profiles for durable clinical responses – the 2nd Next Generation Kinase Inhibitors Summit (February 22-23, Boston, MA).
Top sessions include:
- Sandra Wiley, Director of Translational Science, MEI Pharma speaking on how Voruciclib, a CDK9 inhibitor, downregulates MYC and MCL1 and Inhibits proliferation in heme and solid tumor models
- Greg Jones, Principal Scientist, Pfizer speaking on targeting RAF kinases to overcome adaptive resistance to RAS targeted therapies
- Adar Makovski Silverstein, Director of Corporate Development, Onconova Therapeutics, harnessing multikinase inhibitors to target multiple cancer indications
With the following senior decision makers from leading companies confirmed to be in the room, you don’t want to miss out on this FREE OPPORTUNITY to gather with the key organizations and academics rejuvenating kinase inhibitor development:
- Senior Vice President - Cellestia Biotech
- Director Translational biology – Pathos
- Executive Director, Translational Science - Forma Therapeutics
- Senior Director, Biochemistry - Blueprint Medicines
- Senior Medical Science Liaison - Bayer
- Biochemistry Co-op – Novartis
- Chief Executive Officer – Genosco
- Chief Scientist Officer - Anastasis Bio Corp
- Senior Scientist - Tango Therapeutics
- Principal Scientist - Loxo Oncology at Lilly
